# 510(k) Summary

# Submitter information Contact person:

Neil Parker Senior Regulatory Affairs Specialist

# Address:

Siemens Healthcare Diagnostics 511 Benedict Avenue Tarrytown, NY 10591

# Phone:

914-524-2477   
914-524-2500 (fax)

Date summary prepared: March 28, 2011

Device Trade or Proprietary Names:

ADVIA Chemistry β2-Microglobulin reagent ADVIA Chemistry β2-Microglobulin calibrator

# Device Common/Usual Name or Classification Name:

Beta-2-Microglobulin Immunological Test System Calibrator

Classification Number / Class:

21 CFR 866.5630 - Beta-2-Microglobulin Immunological Test System Class II 21 CFR 862.1150 - Calibrator - Class II

# Product code:

JZG - Beta-2-Microglobulin Immunological Test System JIT - Calibrator, Secondary

This 510(k) summary of safety and effectiveness is being submitted in accordance with the requirements of 21 CFR 807.92.

The assigned 510(k) number is:

# Assay Predicate Device:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>Siemens N Latex β2 - Microglobulin (N B2M)</td></tr><tr><td rowspan=1 colspan=1>Common name</td><td rowspan=1 colspan=1>Beta-2-Microglobulin Immunological TestSystem - Class II</td></tr><tr><td rowspan=1 colspan=1>510(k) Number</td><td rowspan=1 colspan=1>k002731</td></tr><tr><td rowspan=1 colspan=1>Manufacturer</td><td rowspan=1 colspan=1>Siemens (formerly Dade Behring, Inc)</td></tr></table>

# Calibrator Predicate Device

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>Siemens N-protein standard SL</td></tr><tr><td rowspan=1 colspan=1>Common name</td><td rowspan=1 colspan=1>Calibrator, multi-analytemixture</td></tr><tr><td rowspan=1 colspan=1>510(k) Number</td><td rowspan=1 colspan=1>k052788</td></tr><tr><td rowspan=1 colspan=1>Manufacturer</td><td rowspan=1 colspan=1>Siemens (formerly Dade Behring, Inc)</td></tr></table>

# Device Description:

The ADVIA 1650 Chemistry β2-Microglobulin (B2M) assay sample is diluted and reacted with a buffer that contains latex particles coated with antibody specific for $\beta 2 \cdot$ microglobulin. The formation of the antibody-antigen complex during the reaction results in an increase in turbidity, the extent of which is measured as the amount of light absorbed at $5 4 5 \mathsf { n m }$ . The β2-Microglobulin concentration in a sample is determined by constructing a standard curve from the absorbance of a reagent blank and a single-level calibrator.

The ADVIA Chemistry β2-Microglobulin Calibrator is a single analyte, lyophilized, buffer based product containing bovine serum albumin and human β2-Microglobulin. The kit consists of 3 vials of a single level calibrator. The calibrator requires reconstitution with 1mL of distilled water prior to use.

# Statements of Intended Use:

Reagent: for in vitro diagnostic use in the quantitative determination of $\beta 2$ -microglobulin in human serum or plasma (lithium heparin and potassium EDTA) on ADVIA@ 1650 Chemistry systems. The ADVIA 1650 Chemistry $\beta 2$ -Microglobulin (B2M) assay aids in the diagnosis of active rheumatoid arthritis and kidney disease.

Calibrators: for in vitro diagnostic use in the calibration of ADVIA® Chemistry systems for the ADVIA Chemistry $\beta 2$ -Microglobulin method.

# Comparisons to the Predicate Devices: Assay Similarities

<table><tr><td rowspan=1 colspan=1>Items</td><td rowspan=1 colspan=1>ADVIA 1650 Chemistry β2-Microglobulin (B2M) assay</td><td rowspan=1 colspan=1>Siemens N Latex β2-Microglobulin (N B2M)(Predicate Device) k002731</td></tr><tr><td rowspan=1 colspan=3>Similarity</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indication foruse</td><td rowspan=1 colspan=1>for in vitro diagnostic use in thequantitative determination of β2-microglobulin in human serum orplasma (lithium heparin andpotassium EDTA) on ADVIA®1650 Chemistry systems. TheADVIA 1650 Chemistry β2-Microglobulin (B2M) assay aidsin the diagnosis of activerheumatoid arthritis and kidneydisease.</td><td rowspan=1 colspan=1>SimilarThe Siemens N Latex β2 -Microglobulin (N B2M) isIn vitro diagnostic reagent forthe quantitative determinationof β2-microglobulin in humanserum, plasma (EDTA andheparinized), as well as inurine by means of particle-enhanced immuno-nephelometry on the BNSystems. This assay aids inthe diagnosis of renaldysfunction.</td></tr><tr><td rowspan=1 colspan=1>Measurement</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent storage temperature</td><td rowspan=1 colspan=1>2-8°C</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Use of Calibrators</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reference Range</td><td rowspan=1 colspan=1>1.0 to 2.4 mg/L</td><td rowspan=1 colspan=1>Similar1.09 to 2.53 mg/L</td></tr></table>

# Assay Differences

<table><tr><td colspan="1" rowspan="1">Items</td><td colspan="1" rowspan="1">ADVIA 1650 Chemistry β2-Microglobulin (B2M) assay</td><td colspan="1" rowspan="1">Siemens N Latex β2 -Microglobulin (N B2M)(Predicate Device) k002731</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Platform</td><td colspan="1" rowspan="1">ADVIA 1650 Chemistry System</td><td colspan="1" rowspan="1">BN system</td></tr><tr><td colspan="1" rowspan="1">Assay principle</td><td colspan="1" rowspan="1">turbidimetric</td><td colspan="1" rowspan="1">nephelometric</td></tr><tr><td colspan="1" rowspan="1">On Board stability</td><td colspan="1" rowspan="1">21 days</td><td colspan="1" rowspan="1">Minimum 5 days</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum, plasma</td><td colspan="1" rowspan="1">Serum, plasma, urine</td></tr><tr><td colspan="1" rowspan="1">Assay Range</td><td colspan="1" rowspan="1">0.25 - 18.0 mg/L</td><td colspan="1" rowspan="1">0.7 - 23.0 mg/L(serum/plasma)</td></tr><tr><td colspan="1" rowspan="1">Antibody Source</td><td colspan="1" rowspan="1">goat</td><td colspan="1" rowspan="1">mouse</td></tr><tr><td colspan="1" rowspan="1">Items</td><td colspan="1" rowspan="1">ADVIA Chemistry β2-MicroglobulinCalibrator</td><td colspan="1" rowspan="1">Siemens N Protein StandardSL (Predicate Device)k052788</td></tr><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indication foruse</td><td colspan="1" rowspan="1">for in vitro diagnostic use thecalibration of ADVIA® Chemistrysystems for the ADVIA Chemistryβ2-Microglobulin method.</td><td colspan="1" rowspan="1">SimilarFor in vitro diagnostic use forestablishment of referencecurves for the determinationof 27 analytes includingβ2-Microglobulinon the BN Systems.</td></tr><tr><td colspan="1" rowspan="1">Number of calibrators</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrator storage temperature</td><td colspan="1" rowspan="1">2-8C</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Fill volume</td><td colspan="1" rowspan="1">1.0mL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">WHO 1 International Standard</td><td colspan="1" rowspan="1">Same</td></tr></table>

# Calibrator Differences

<table><tr><td rowspan=1 colspan=1>Items</td><td rowspan=1 colspan=1>ADVIA Chemistry β2-MicroglobulinCalibrator</td><td rowspan=1 colspan=1>Siemens N Protein StandardSL (Predicate Device)k052788</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Single</td><td rowspan=1 colspan=1>Multi</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized - buffer based</td><td rowspan=1 colspan=1>Liquid - serum based</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>30 days after reconstitution</td><td rowspan=1 colspan=1>14 days after opening</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>ADVIA 1650 Chemistry System</td><td rowspan=1 colspan=1>BN Systems</td></tr></table>

# Performance:

Substantial equivalence for the ADVIA 1650 Chemistry β2-Microglobulin assay to the predicate device was demonstrated by testing several method performance characteristics including analytical sensitivity, linearity, imprecision, method comparison and interfering substances. The following information summarize the analytical sensitivity, linearity, precision (total), interfering substances, serum / plasma equivalency and method comparison results.

All of the evaluation studies gave acceptable results compared to the predicate device. These studies support that the ADVIA 1650 Chemistry β2-Microglobulin assay is substantially equivalent to the Siemens N Latex β2 -Microglobulin (N B2M) that is currently marketed.

# Analytical Sensitivity

The Limit of Detection (LoD) and Limit of Blank (LoB) were determined by following CLSI guideline EP-17A. The study was performed by running 60 replicates of a blank (serum sample with a low concentration of β2-Microglobulin at $< 0 . 2 0 \mathrm { m g / L }$ ) and 60 replicates of a low serum sample (serum sample with approximate concentration of 0.74mg/L). The following results were obtained:

$\mathsf { L o B } = 0 . 2 0 \mathsf { m g / L }$ $\mathsf { L o D } = 0 . 2 5 ~ \mathsf { m g / L }$

# Imprecision

Imprecision was assessed by assaying 4 serum based samples 2 times per run, 2 runs per day, for at least 20 days. Precision estimates were calculated according to CLSl document EP5-A2. The following results were obtained.

Table 1 - summary of Precision for the ADVIA 1650 Chemistry β2-Microglobulin (B2M) assay

<table><tr><td rowspan=1 colspan=2>ADVIA 1650 Chemistry β2-Microglobulin (B2M) assay</td></tr><tr><td rowspan=1 colspan=1>Level (mg/L)</td><td rowspan=1 colspan=1>Total CV (%)n = 80</td></tr><tr><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>3.68</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>12.52</td><td rowspan=1 colspan=1>2.1</td></tr></table>

# Interfering Substances

Interfering substances were tested at β2-microglobulin concentrations of approximately 1, 3 and 11 mg/L on the ADVIA 1650 chemistry β2-microglobulin assay. Table 2 summarizes the data for bilirubin (conjugated and unconjugated), hemolysis, lipemia (from intralipid), rheumatoid factor and ascorbic acid. Table 3 summarizes the data for acetone, cholesterol, creatinine, ethanol, glucose, IgG, IgM, riboflavin, total protein, urea, and uric acid.

Table 2   

<table><tr><td>Interferent</td><td>Interferent Level</td><td>β.-Microglobulin Sample Concentration</td><td>Interference</td></tr><tr><td>Bilirubin</td><td>60 mg/dL</td><td>1.14 mg/L</td><td>NSI*</td></tr><tr><td>(conjugated and</td><td>(1026 μmol/L)</td><td>10.95 mg/L</td><td>NSI*</td></tr><tr><td>unconjugated)</td><td></td><td></td><td></td></tr><tr><td>Hemolysis</td><td>1000 mg/dl</td><td>1.27 mg/L</td><td>NSI*</td></tr><tr><td>(hemoglobin)</td><td>(10.0 g/L)</td><td>11.00 mg/L</td><td>NSI*</td></tr><tr><td>Lipemia**</td><td>1000 mg/dL</td><td>1.20 mg/L</td><td>NSI*</td></tr><tr><td>(from Intralipid)</td><td>(11.3 mmol/L)</td><td>11.03 mg/L</td><td>NSI*</td></tr><tr><td>Rheumatoid Factor (RF)</td><td>2500 IU/mL</td><td>1.16 mg/L</td><td>NSI*</td></tr><tr><td>;</td><td></td><td>10.30 mg/L</td><td>NSI*</td></tr><tr><td>Ascorbic Acid</td><td>50 mgidL</td><td>1.21 mg/L</td><td>NSI*</td></tr><tr><td></td><td>100 mg/dL</td><td>1.21 mg/L</td><td>-15.3%</td></tr><tr><td></td><td>150 mg/dL</td><td>10.73 mg/l</td><td>NSI*</td></tr><tr><td></td><td>200 mg/dl</td><td>10.73 mg/L</td><td>-13.4%</td></tr></table>

$\star \mathsf { N S l } = \mathsf { N O }$ Sinint Interenc pentag  0%s nderd  niant nte

Table 3   

<table><tr><td>Substance in Serum</td><td>Concentration Tested</td><td>Interference</td></tr><tr><td>Acetone</td><td>up to 250 mg/dl</td><td>NSI*</td></tr><tr><td>Cholesterol</td><td>up to 500 mg/dL</td><td>NSI*</td></tr><tr><td>Creatinine</td><td>up to 125 mg/dL</td><td>NSI*</td></tr><tr><td>Ethanol</td><td>up to 1000 mg/dL</td><td>NSI*</td></tr><tr><td>Glucose</td><td>up to 2000 mg/dL</td><td>NSI*</td></tr><tr><td>Immunoglobulin G</td><td>up to 5000 mg/dL</td><td>NSI*</td></tr><tr><td>Immunoglobulin M</td><td>up to 1600 mg/dL</td><td>NSI*</td></tr><tr><td>Riboflavin</td><td>up to 15 mg/dL</td><td>NSI*</td></tr><tr><td>Total protein</td><td>up to 12 gidL</td><td>NSI*</td></tr><tr><td>Urea</td><td>up to 60 mg/dL</td><td>NSI*</td></tr><tr><td>Uric acid</td><td>up to 12 mg/dl</td><td>NSI*</td></tr></table>

EY $\bf \Pi ^ { \star } \sf N S l = \sf N o$ Significant Interference. A percentage effect $\geq 1 0 \%$ iscnnn

# Correlation

A total of 88 samples serum samples were analyzed on the ADVIA 1650 Chemistry system using $\beta 2$ -Microglobulin reagent and on the Siemens N Latex β2 -Microglobulin (predicate device), in parallel on the same day to demonstrate the equivalence of the two methods.

Table 4 summarizes the data.

Table 4 - ADVIA 1650 Chemistry β2-microglobulin assay vs. Siemens N Latex β2 - Microglobulin (N B2M) method   

<table><tr><td rowspan=1 colspan=6>Siemens N Latex β2 -Microglobulin vs ADVIA 1650 Chemistry B2MAssay</td></tr><tr><td rowspan=1 colspan=1>X Axis</td><td rowspan=1 colspan=1>Y Axis</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Y-int</td></tr><tr><td rowspan=1 colspan=1>Siemens NLatex β2 -Microglobulin</td><td rowspan=1 colspan=1>ADVIA 1650ChemistryB2M</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>-0.38</td></tr></table>

# Serum / Plasma (lithium heparin and EDTA)

The ADVIA 1650 Chemistry Centaur $\beta 2$ -microglobulin assay was evaluated using different sample tube collection types. A matrix study was performed using matched specimens drawn in different tube types, potassium EDTA and lithium heparin. β2- microglobulin values ranged from 0.97 to $1 7 . 7 5 \mathsf { m g / L }$ . Linear regression analysis was performed using the following:

serum $( { \pmb x } )$ Vs. potassium EDTA (y1) serum $( { \pmb x } )$ vs. lithium heparin (y2)

No significant differences between tube types was observed. The following results were obtained:

Table 5   

<table><tr><td>Specimen Type</td><td>Comparison Assay (x)</td><td>N</td><td>Regression Equation</td><td>Sy.x</td><td>r</td><td>Sample Range</td></tr><tr><td>Plasma (K, EDTA)</td><td>ADVIA 1650/1800 B2M Reagent</td><td>57</td><td>y = 1.00x - 0.04</td><td>0.19</td><td>0.99</td><td>0.97-17.75 mg/L</td></tr><tr><td>Plasma (Lithium Heparin)</td><td>ADVIA 1650/1800 B2M Reagent</td><td>57</td><td>y = 1.01x + 0.01</td><td>0.21</td><td>0.99</td><td>0.97-17.75 mgil</td></tr></table>

# Conclusions:

The Siemens Healthcare Diagnostics ADVIA 1650 Chemistry Centaur $\beta 2$ -microglobulin assay ADVIA is substantially equivalent to other products in commercial distribution intended for similar use. Most notably, it is substantially equivalent to the currently marketed Siemens N Latex β2 -Microglobulin (N B2M) k002731.

The Siemens Healthcare Diagnostics ADVIA Chemistry $\beta 2$ -Microglobulin calibrator is substantially equivalent to other products in commercial distribution intended for similar use. Most notably, it is substantially equivalent to the currently marketed Siemens N Protein Standard SL k052788.

Siemens Healthcare Diagnostics, Inc. c/o Mr. Neil Parker   
Sr. Regulatory Affairs Specialist   
511 Benedict Ave   
Tarrytown, NY 10591

Re: k110874 ADVIA $^ \mathrm { \textregistered }$ Chemistry $\beta 2$ -Microglobulin Reagent Regulation Number: 21 CFR $\ S 8 6 6 . 5 6 3 0$ Regulation Name: Beta-2-Microglobulin Immunological Test System Regulatory Class: II Product Code: JZG, JIT Dated: January 10, 2012 Received: January 12, 2012

Dear Mr. Parker:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter

Page 2 - Mr. Neil Parker

will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Rleeva Philip

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known): _ k 110 874   
Device Name: ADVIA 1650 Chemistry β2-microglobulin (B2M) method   
Indication for Use:

Reagent: for in vitro diagnostic use in the quantitative determination of $\beta 2$ -microglobulin in human serum or plasma (lithium heparin and potassium EDTA) on ADVIA 1650 Chemistry systems. The ADVIA 1650 Chemistry $\beta 2$ -Microglobulin (B2M) assay aids in the diagnosis of active rheumatoid arthritis and kidney disease.

Calibrator: for in vitro diagnostic use in the calibration of ADVIA $\otimes$ Chemistry systems for the ADVIA Chemistry 02-Microglobulin method

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/cbd952d846cca1ba7d5a11e100d97e722c60a2de100a4d7ccf0232414718bf98.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety